Evonik
Tuesday, February 16, 2021
10:00 a.m. EST / 4:00 p.m. CET

How novel technology is crushing bioavailability barriers in omega-3 supplementation

Back to overview

Overview

Only around ten percent of the world’s population have a healthy dietary intake of omega-3 fatty acids. For everyone else, food supplements may be the solution. However, fish oil as a main source of omega-3 fatty acids is a finite resource and the nutraceutical industry is in dire need of next generation supplements to close nutritional gaps. Our webinar will highlight recent scientific evidence for a novel technology that maximizes the value of omega-3 fatty acid supplements.

In this webinar, our experts Christopher Studte and Laura Headley will review findings from the first-in-human study, published in December 2020 in the journal Prostaglandins, Leukotrienes and Essential Fatty Acids, on the increased bioavailability of omega-3 EPA and DHA when used in combination with the amino acid L-lysine.1

Furthermore, an omega-3 lysine complex has many advantages over a typical commercially available oil-based ethyl-ester soft gel formulation, particularly with respect to consumer convenience. Our experts will take you through the nutritional science behind it all and answer your questions live.
The webinar will also touch upon the question of whether novel combination products may even require lower doses and therefore increase the sustainability profile of omega-3 supplements.

Don’t miss this webinar if you want to stay ahead of the emerging technology and evidence shaping the omega-3 market. We are looking forward to e-meeting you on February 16, 2021.

Experts featuring this session

Dr. Laura Headley
Nutritional Scientist
Vita
Dr. Headley is a Nutritional Scientist at Evonik where she leverages her scientific and nutraceutical expertise to support the development of advanced food ingredients and co-ordinate related clinical trials.

Before joining Evonik in 2018, she was a registered Dietitian and Nutritional Scientist for more than 13 years.

She earned a PhD from the University of Surrey, Guildford, UK in the field of human nutrition and cardiovascular disease, followed by several years as a Post-Doctoral Research Fellow, where she gained extensive experience in the planning, management and reporting of nutrition-focused clinical trials.
Dr. Christopher Studte
Director New Health Ingredients
Vita
Dr. Studte has been the Director of New Health Ingredients at Evonik since 2017. During that time, he has coordinated the development and commercial adoption of Evonik’s omega-3 platform across multiple international regions. In parallel, he has supported a number of nutraceutical companies to develop new formulations with omega-3 powder ingredients.

He has also held other senior roles at Evonik in R&D and technical marketing. He received his Ph.D. in organic chemistry from Albert-Ludwigs-Universität Freiburg in Germany. As a post-doctoral research fellow at the University of Japan, he undertook multiple projects in the field of medicinal chemistry.

Register now

Details

Webinar language
English

Venue

Online

Questions?

Julia Born
Market Communications Health Care
+49 6151 18 4984 E-Mail
Register now
Evonik Health Care
Company Information
Legal Notice
Privacy Policy